Ga-DPI-4452
PreclinicalSmall molecule
Ga-DPI-4452 is one of 3 small molecule programs targeting Clear Cell Renal Cell Cancer (ccRCC). It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in Clear Cell Renal Cell Cancer (ccrcc)
#DrugCompanyPhaseTrials
1Zanzalintinib
Merck & Co.Phase 2
Envafolimab+lenvatinib
33D Medicines (Sichuan) Co., Ltd.
Phase 2
Ga-DPI-4452
IITM Oncologics GmbH
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Clear Cell Renal Cell Cancer (ccRCC)1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ga-DPI-4452. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- IITM Oncologics GmbH